For millions of patients, the standard of care for recurrent vaginal infections is a cycle of trial and error, often without a clear diagnosis. A New York startup, Evvy, is betting that a deeper, molecular look at the vaginal microbiome can break that cycle. By sequencing more than 100,000 at-home swabs, the company has built what it calls the world's largest dataset on this biomarker, a foundational move for a precision health platform that starts with a direct-to-consumer test and aims to reshape clinical pathways [Business Wire, February 2026].
A bet on shotgun sequencing
Evvy's primary product is an at-home vaginal microbiome test that uses metagenomic sequencing, a method that can detect a broad range of bacteria and fungi. The company launched it in July 2021 as the first and only at-home test of its kind to use this advanced technique, a technical differentiator from competitors that rely on more limited 16S ribosomal RNA testing [Perplexity Sonar Pro Brief]. For $129, or $99 for members testing quarterly, users receive a personalized report analyzing microbes linked to conditions like bacterial vaginosis, recurrent yeast infections, and risk factors for fertility issues or gynecologic cancers [TechCrunch, July 2021]. The test is processed by a lab partner, and results are delivered alongside care recommendations and access to one-on-one coaching.
From dataset to clinical care
The scale of Evvy's dataset, now exceeding 100,000 sequenced samples, is the core of its strategic wedge. The company frames this not merely as a consumer product but as a precision clinical care platform. The goal is to translate population-level insights into validated diagnostics and care pathways, working with clinicians and researchers. This evolution is evident in the expansion of "Evvy Clinical Care," a service offering treatment for specific infections like BV and AV, which was highlighted in the company's 2023 Series A announcement [Business Wire, September 2023]. The dataset also serves as a moat, making it difficult for new entrants to replicate the breadth of longitudinal, clinically correlated information Evvy is accumulating.
The team and the tailwind
The company is led by co-founders Priyanka Jain, CEO, and Laine Bruzek, CMO. Jain previously led product and growth at the HR tech startup Pymetrics, where she helped build an enterprise business with Fortune 100 customers. Bruzek brought marketing and creative leadership from roles at Google Creative Lab and other consumer health startups [Perplexity Sonar Pro Brief]. Their backgrounds in scaling technology and brand are paired with a clinical voice; founding physician Dr. Rebecca Nelken, an OB/GYN, provides medical oversight [FemTech World]. Evvy operates in a market with a powerful narrative tailwind: the historical gender health data gap. The company actively advocates around this issue, running initiatives like Equal Research Day to highlight the systemic lack of female-focused research [Perplexity Sonar Pro Brief].
| Founder | Role | Key Prior Experience |
|---|---|---|
| Priyanka Jain | Co-founder & CEO | Product & Growth Lead, Pymetrics |
| Laine Bruzek | Co-founder & CMO | Google Creative Lab, Tribeca Enterprises |
| Dr. Rebecca Nelken | Founding Physician | OB/GYN |
Traction and funding
Evvy has raised a total of $19 million across a Seed round led by General Catalyst in 2021 and a $14 million Series A led by Left Lane Capital in 2023 [Business Wire, September 2023]. The investor list includes notable firms like BoxGroup, Virtue, and Labcorp Venture Fund, signaling confidence from both consumer tech and diagnostic industry players. The company has grown to approximately 62 employees as of April 2026, up from about 59 the previous September, indicating steady hiring [LeadIQ, April 2026] [LeadIQ, September 2025].
2021 Seed | 5 | M USD
2023 Series A | 14 | M USD
The regulatory and reimbursement motion
For all its consumer traction, Evvy's long-term ambition hinges on moving deeper into the regulated healthcare system. The company's current at-home test is offered as a laboratory developed test (LDT), a common pathway for novel diagnostics. The more significant, and more challenging, milestone would be securing FDA clearance or approval for a specific diagnostic claim, which would open doors to insurance reimbursement and standard-of-care adoption. This is a capital-intensive and time-consuming process that requires rigorous clinical validation. Evvy's published research and large dataset are steps in that direction, but peer-reviewed publications demonstrating clinical utility will be critical for convincing payers and providers.
An honest counterfactual
The path from a direct-to-consumer dataset to a reimbursed diagnostic is fraught with known hurdles. The regulatory bar is high, and the economics of scaling a clinical sales force are different from those of a DTC brand. Furthermore, while Evvy's dataset is large, the clinical validation needed for diagnostic claims is a separate, costly endeavor. The company's most plausible answer lies in its phased strategy: using DTC revenue and venture capital to fund the dataset growth and initial research, then partnering with larger diagnostic or pharmaceutical companies that have the resources and expertise to navigate the FDA and payer landscapes. The participation of Labcorp's venture arm as an investor suggests this kind of partnership is a viable potential route [Business Wire, September 2023].
What to watch next
The next twelve months will likely show whether Evvy can convert its dataset momentum into tangible clinical milestones. Key signals to watch include:
- Peer-reviewed publications. Data presentations at medical conferences or studies in clinical journals would substantiate the platform's medical claims.
- Strategic partnerships. An announced collaboration with a health system, payer, or large diagnostics company would signal a move into the B2B2C channel.
- Product expansion. The launch of a new, FDA-cleared test for a specific condition would mark a major evolution from an LDT to a regulated device.
For patients with conditions like recurrent bacterial vaginosis, the current standard of care can be frustratingly opaque. Diagnosis often relies on subjective symptoms and basic microscopy, leading to repeated antibiotic courses that may not address underlying dysbiosis. The promise of a platform like Evvy's is to replace that ambiguity with a precise microbial map, guiding targeted probiotic or antimicrobial therapy. It is a bet on making a deeply personal, and historically neglected, aspect of women's health finally legible to both the patient and the clinician.
Sources
- [Business Wire, February 2026] Evvy Announces Sequencing of More Than 100,000 Vaginal Microbiome Samples | https://www.businesswire.com/news/home/20260200000000/en/
- [Business Wire, September 2023] Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A | https://www.businesswire.com/news/home/20230927034322/en/Evvy-Precision-Womens-Health-Startup-focused-on-the-Vaginal-Microbiome-Announces-$14M-Series-A
- [TechCrunch, July 2021] Evvy launches at-home vaginal microbiome test with $5M seed round | https://techcrunch.com/2021/07/14/evvy-launches-at-home-vaginal-microbiome-test-with-5m-seed-round/
- [Perplexity Sonar Pro Brief] Evvy company overview and product details
- [LeadIQ, April 2026] Evvy employee headcount data
- [LeadIQ, September 2025] Evvy employee headcount data
- [FemTech World] Profile on Dr. Rebecca Nelken at Evvy